Poor immunogenicity upon SARS-CoV-2 mRNA vaccinations in autoimmune SLE patients is associated with pronounced EF-mediated responses and anti-BAFF/Belimumab treatment
Preprint
Abstract
Novel mRNA vaccines have resulted in a reduced number of SARS-CoV-2 infections and hospitalizations. Yet, there is a paucity of studies regarding their effectiveness on immunocompromised autoimmune subjects. In this study, we enrolled subjects naïve to SARS-CoV-2 infections from two cohorts of healthy donors (HD, n=56) and systemic lupus erythematosus (SLE, n=69). Serological assessments of their circulating antibodies revealed a significant reduction of potency and breadth of neutralization in the SLE group, only partially rescued by a 3 rd booster dose. Immunological memory responses in the SLE cohort were characterized by a reduced magnitude of spike-reactive B and T cell responses that were strongly associated with poor seroconversion. Vaccinated SLE subjects were defined by a distinct expansion and persistence of a DN2 spike-reactive memory B cell pool and a contraction of spike-specific memory cTfh cells, contrasting with the sustained germinal center (GC)-driven activity mediated by mRNA vaccination in the healthy population. Among the SLE-associated factors that dampened the vaccine responses, treatment with the monoclonal antibody anti-BAFF/Belimumab (a lupus FDA-approved B cell targeting agent) profoundly affected the vaccine responsiveness by restricting the de novo B cell responses and promoting stronger extra-follicular (EF)-mediated responses that were associated with poor immunogenicity and impaired immunological memory. In summary, this study interrogates antigen-specific responses and characterized the immune cell landscape associated with mRNA vaccination in SLE. The identification of factors associated with reduced vaccine efficacy illustrates the impact of SLE B cell biology on mRNA vaccine responses and provides guidance for the management of boosters and recall vaccinations in SLE patients according to their disease endotype and modality of treatment.Keywords
This publication has 103 references indexed in Scilit:
- CCR6 is transiently upregulated on B cells after activation and modulates the germinal center reaction in the mouseImmunology & Cell Biology, 2013
- The discovery and development of belimumab: the anti-BLyS–lupus connectionNature Biotechnology, 2012
- BAFF/APRIL Inhibition Decreases Selection of Naive but Not Antigen-Induced Autoreactive B Cells in Murine Systemic Lupus ErythematosusThe Journal of Immunology, 2011
- BelimumabNature Reviews Drug Discovery, 2011
- Interferon‐α induces unabated production of short‐lived plasma cells in pre‐autoimmune lupus‐prone (NZB×NZW)F1 mice but not in BALB/c miceEuropean Journal of Immunology, 2011
- B cells as therapeutic targets in SLENature Reviews Rheumatology, 2010
- Effect of long‐term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double‐blind, placebo‐controlled, dose‐ranging studyArthritis & Rheumatism, 2009
- Dysregulation of germinal centres in autoimmune diseaseNature Reviews Immunology, 2009
- Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cellsBlood, 2005
- IFN‐α/β enhances BCR‐dependent B cell responsesInternational Immunology, 2002